argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 48.98B |
| Revenue (ttm) | 3.14B |
| Net Income (ttm) | 1.31B |
| Shares Out | 61.20M |
| EPS (ttm) | 19.83 |
| PE Ratio | 40.35 |
| Forward PE | 37.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,338 |
| Average Volume | 83,435 |
| Open | 801.00 |
| Previous Close | 800.40 |
| Day's Range | 798.40 - 802.20 |
| 52-Week Range | 456.60 - 810.00 |
| Beta | -0.11 |
| RSI | 73.26 |
| Earnings Date | Oct 30, 2025 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
News
Guru Fundamental Report for ARGX - Benjamin Graham
Below is Validea's guru fundamental report for ARGENX SE - ADR (ARGX). Of the 22 guru strategies we follow, ARGX rates highest using our Value Investor model based on the published strategy of Benjami...
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 14.79% on an annualized basis producing an average annual return of 27.84%. Currently, argenx has a market capitalization of...
Citigroup Boosts Price Target for ARGX While Maintaining Buy Rating | ARGX Stock News
Citigroup Boosts Price Target for ARGX While Maintaining Buy Rating | ARGX Stock News
PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with...
Wedbush Raises Price Target for ARGX to $1000, Maintains Outperform Rating | ARGX Stock News
Wedbush Raises Price Target for ARGX to $1000, Maintains Outperform Rating | ARGX Stock News
KROS vs. ARGX: Which Stock Is the Better Value Option?
KROS vs. ARGX: Which Stock Is the Better Value Option?
ARGX: JP Morgan Raises Price Target, Maintains Overweight Rating | ARGX Stock News
ARGX: JP Morgan Raises Price Target, Maintains Overweight Rating | ARGX Stock News
Baron International Growth Fund Q3 2025 Contributors And Detractors
Baron International Growth Fund gained 6.04% during the quarter, slightly underperforming its benchmark, the MSCI ACWI ex USA Index. Lynas Rare Earths' shares nearly doubled during the quarter as geop...
Argenx Gains Health Canada Approval For Vyvgart SC As Monotherapy In CIDP
(RTTNews) - argenx SE (ARGX), Wednesday, announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC as a monotherapy for the treatment of adult patients with active chronic ...
Argenx (ARGX) Gains Health Canada Approval for CIDP Treatment
Argenx (ARGX) Gains Health Canada Approval for CIDP Treatment
Biotech is back. Here's why these rallying stocks belong in your portfolio now.
The volatile sector is seeing greater stability, and these four stocks can profit.
ARGX Receives Buy Rating and Raised Price Target by TD Cowen | ARGX Stock News
ARGX Receives Buy Rating and Raised Price Target by TD Cowen | ARGX Stock News
RBC Capital Raises Price Target for ARGX, Maintains Outperform Rating | ARGX Stock News
RBC Capital Raises Price Target for ARGX, Maintains Outperform Rating | ARGX Stock News
Evercore ISI Group Raises Price Target for argenx (ARGX) to $910 | ARGX Stock News
Evercore ISI Group Raises Price Target for argenx (ARGX) to $910 | ARGX Stock News
argenx SE (ARGX) Q3 2025 Earnings Call Transcript
argenx SE ( ARGX) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Tim Van Hauwermeiren - C...
argenx SE (ARGNF) Q3 2025 Earnings Call Highlights: Record Sales and Strategic Pipeline Advancements
argenx SE (ARGNF) Q3 2025 Earnings Call Highlights: Record Sales and Strategic Pipeline Advancements
Q3 2025 argenx SE Earnings Call Transcript
Q3 2025 argenx SE Earnings Call Transcript
argenx SE 2025 Q3 - Results - Earnings Call Presentation
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports
Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.
Argenx (ARGX) Reports Strong Q3 Earnings and Revenue Growth
Argenx (ARGX) Reports Strong Q3 Earnings and Revenue Growth
argenx SE beats top-line and bottom-line estimates; reaffirms FY25 outlook
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any b...
Argenx (ARGX) Reports Positive Results for Vyvgart in Myasthenia Gravis Study
Argenx (ARGX) Reports Positive Results for Vyvgart in Myasthenia Gravis Study
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity Final ADAPT SC+ results sho...